Press Releases about Immunovant Inc![]()
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
December 20, 2023
From Roivant Sciences
Via GlobeNewswire
![]()
Immunovant Inc. (NASDAQ: IMVT) Records 52-Week High Tuesday Morning
September 26, 2023
![]() ![]() ![]() Via NewMediaWire
Topics
Lawsuit
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
October 05, 2022
Topics
Death
Exposures
Death
![]() Via NewMediaWire
Topics
Lawsuit
![]() Via NewMediaWire
Topics
Lawsuit
![]() ![]() Via NewMediaWire
Topics
Lawsuit
![]() Via NewMediaWire
Topics
Lawsuit
![]() Via NewMediaWire
Topics
Lawsuit
NASDAQ:IMVT Investor Notice: Deadline on April 20, 2021 in Lawsuit Against Immunovant, Inc.
April 07, 2021
Via SBWire
Topics
Lawsuit
![]() Via NewMediaWire
Topics
Lawsuit
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |